Audit 390626

FY End
2024-06-30
Total Expended
$1.70M
Findings
2
Programs
2
Year: 2024 Accepted: 2026-03-06
Auditor: BWK ROGERS PC

Organization Exclusion Status:

Checking exclusion status...

Findings

ID Ref Severity Repeat Requirement
1176719 2024-003 Material Weakness Yes L
1176720 2024-003 Material Weakness Yes L

Programs

ALN Program Spent Major Findings
93.103 Food and Drug Administration Research $712,681 Yes 1
47.041 Engineering $46,368 Yes 0

Contacts

Name Title Type
RKVKGV1CJDB8 Vadim Gurvich Auditee
6126266650 O. Barry Rogers Auditor
No contacts on file

Notes to SEFA

The accompanying schedule of expenditures of federal awards (the “Schedule”) includes the federal grant activity of National Institute for Pharmaceutical Technology and Education, Inc. under programs of the federal government for the year ended June 30, 2024. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of National Institute for Pharmaceutical Technology and Education, Inc., it is not intended to and does not present the financial position, changes in net assets, or cash flows of National Institute for Pharmaceutical Technology and Education, Inc.
Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years.
National Institute for Pharmaceutical Technology and Education, Inc. has elected not to use the 10% de minimis indirect cost rate allowed under the Uniform Guidance.

Finding Details

Assistance Listing Number 93.103 Food and Drug Administration Research Grant Numbers 1U01FD00758-01 and 5U01FD04275-08 REV 4 US Department of Health and Human Services Finding 2024-003 Compliance Requirement: Filing of Single Audit Report Type of Finding: Material Weakness Criteria: Pursuant to 2 CFR section 200.512(a), the audit, data collection form, and reporting package must be submitted within 30 calendar days after receipt of the auditor’s report(s) or nine months after the end of the audit period (whichever is earlier). Condition: The Organization did not submit the Single Audit Reporting Package for the year ended June 30, 2024, within nine months after the end of the audit period (March 31, 2025). Cause: The Organization had transition in key financial personnel in January 2025. Audit fieldwork had to be delayed while the new part-time outsourced personnel worked to ensure that the records were complete and reconciled. After the auditor performed planning and made selections, additional changes were made to the financial records without being communicated to the auditor, causing further delays. Additional review of these changes resulted in more discussion and further changes, which were completed in December 2025. It then took the auditor additional time to get the testing back onto their schedule and complete the testing. Effect or potential effect: Failure to submit the required Single Audit Reporting Package timely automatically results in the Organization not qualifying for low-risk auditee status for the subsequent year’s Single Audit. Delinquent submission may also result in the inability to receive federal funding. Questioned Costs: None Repeat finding: No Recommendation: We recommend that the Organization update their policies and procedures to avoid delays in completion of the audit and to ensure timely submission of the Reporting Package. Views of responsible officials: Management agrees with the recommendation and will work to ensure future audits are completed timely.